Grynpas M D, Acito A, Kasra M
Centre for Biomaterials, University of Toronto, Canada.
Ann Oncol. 1994;5 Suppl 7:S49-51.
Pamidronate (Aredia) has been used in the treatment of hypercalcemia of malignancy, in Paget's disease of bone, and in osteoporosis to prevent bone resorption. In a 3-month study, intermittent intravenous infusions of pamidronate in dogs did not change the mechanical properties of cortical bone, either in torsion or bending. However, such treatment increased the compressive stiffness and torsional strength of trabecular specimens taken from vertebrae. In a 1-year study, oral administration of pamidronate at various doses produced a linear increase in the elastic modulus of trabecular bone with the square root of the dose and no change in cortical bone. Finally, in a 2-year study (1 year on pamidronate followed by 1 year recovery), no differences were found in the mechanical properties of whole bone whatever dose was given.
帕米膦酸盐(阿可达)已被用于治疗恶性肿瘤引起的高钙血症、佩吉特骨病以及骨质疏松症以防止骨质吸收。在一项为期3个月的研究中,对犬间歇性静脉输注帕米膦酸盐,无论是在扭转还是弯曲方面,都未改变皮质骨的力学性能。然而,这种治疗增加了取自椎骨的小梁标本的抗压刚度和抗扭强度。在一项为期1年的研究中,口服不同剂量的帕米膦酸盐使小梁骨的弹性模量随剂量的平方根呈线性增加,而皮质骨未发生变化。最后,在一项为期2年的研究中(1年使用帕米膦酸盐,随后1年恢复),无论给予何种剂量,全骨的力学性能均未发现差异。